Vanguard Group
RAPT

Vanguard Group’s RAPT Therapeutics RAPT Stock Holding History

Vanguard Group’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$40.2M Buy
1,186,791
+490,603
+70% +$15.2M ﹤0.01% 2285
2025
Q3 		$18M Sell
696,188
-183,861
-21% -$2.41M ﹤0.01% 2671
2025
Q2 		$7.04M Sell
880,049
-154,801
-15% -$1.18M ﹤0.01% 3084
2025
Q1 		$10.1M Buy
1,034,850
+667,181
+181% +$6.56M ﹤0.01% 2840
2024
Q4 		$4.65M Sell
367,669
-26,832
-7% -$341K ﹤0.01% 3302
2024
Q3 		$6.34M Buy
394,501
+5,967
+2% +$121K ﹤0.01% 3168
2024
Q2 		$9.48M Buy
388,534
+76,928
+25% +$3.55M ﹤0.01% 2964
2024
Q1 		$22.4M Buy
311,606
+54,578
+21% +$7.59M ﹤0.01% 2547
2023
Q4 		$51.1M Buy
257,028
+4,115
+2% +$509K ﹤0.01% 2181
2023
Q3 		$33.6M Buy
252,913
+9,544
+4% +$1.56M ﹤0.01% 2318
2023
Q2 		$36.4M Buy
243,369
+45,679
+23% +$7.11M ﹤0.01% 2332
2023
Q1 		$29M Buy
197,690
+9,293
+5% +$1.88M ﹤0.01% 2430
2022
Q4 		$29.8M Buy
188,397
+27,908
+17% +$4.47M ﹤0.01% 2431
2022
Q3 		$30.9M Buy
160,489
+2,296
+1% +$434K ﹤0.01% 2420
2022
Q2 		$23.1M Buy
158,193
+5,125
+3% +$683K ﹤0.01% 2571
2022
Q1 		$26.9M Buy
153,068
+2,274
+2% +$430K ﹤0.01% 2616
2021
Q4 		$44.3M Buy
150,794
+15,933
+12% +$4.26M ﹤0.01% 2419
2021
Q3 		$33.5M Buy
134,861
+20,621
+18% +$5.45M ﹤0.01% 2585
2021
Q2 		$29.1M Buy
114,240
+20,315
+22% +$3.8M ﹤0.01% 2643
2021
Q1 		$16.7M Buy
93,925
+2,276
+2% +$375K ﹤0.01% 2881
2020
Q4 		$14.5M Buy
91,649
+18,521
+25% +$4.03M ﹤0.01% 2801
2020
Q3 		$18.8M Buy
73,128
+15,983
+28% +$3.55M ﹤0.01% 2487
2020
Q2 		$13.3M Buy
57,145
+22,111
+63% +$3.42M ﹤0.01% 2626
2020
Q1 		$5.96M Buy
35,034
+17,069
+95% +$3.89M ﹤0.01% 2891
2019
Q4 		$3.97M Buy
+17,965
New +$3.31M ﹤0.01% 3244

Other funds holding RAPT

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group's RAPT Position: Q4 2025 in Review

Vanguard Group increased its RAPT Therapeutics (RAPT) stake by 70% in Q4 2025, buying an estimated $15.2M and bringing the position to 1,186,791 shares worth $40.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2285.

Vanguard Group first reported a position in RAPT in Q4 2019 and has held it in 25 quarters since. The position peaked at $51.1M in Q4 2023. 105 funds tracked by Wall St. Rank hold RAPT as of Q4 2025.

  • Vanguard Group held 1,186,791 shares of RAPT Therapeutics worth $40.2M as of Q4 2025.
  • Vanguard Group bought 490,603 RAPT Therapeutics shares in Q4 2025, an estimated $15.2M.
  • RAPT Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2285 holding.
  • Vanguard Group first reported a position in RAPT Therapeutics in Q4 2019 and has held it in 25 quarters since.
  • Vanguard Group's RAPT Therapeutics position peaked at $51.1M in Q4 2023.
  • 105 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.